Adding Rigor to Stroke Rate Investigations in Patients with Atrial Fibrillation

Circulation

Volumn 135, Issue 3, 2017, Pages 220-223

  Nielsen, Peter Brønnum ^a,b   Lip, Gregory Y H ^a,c  

^a AALBORG UNIVERSITY   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

atrial fibrillation; Editorials

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; ETHNICITY; HUMAN; MORBIDITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGOR; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; ATRIAL FIBRILLATION; HUMANS; RISK FACTORS; STROKE; THROMBOEMBOLISM;

EID: 85009901984     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.025944     Document Type: Review

References (15)

1. Quinn GR, Severdija ON, Chang Y, Singer DE. Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation. Circulation. 2017;135:208-219. doi: 10.1161/CIRCULATIONAHA.116.024057.
2. Nielsen PB, Larsen TB, Lip GY. Misconceptions on interpretation of risk prediction tools in atrial fibrillation. Am J Med. 2016;129:e31. doi: 10.1016/j.amjmed.2015.11.038.
3. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011;4:14-21. doi: 10.1161/CIRCOUTCOMES.110.958108.
4. Proietti M, Lip GY. Major outcomes in atrial fibrillation patients with one risk factor: impact of time in therapeutic range observations from the SPORTIF trials. Am J Med. 2016;129:1110-1116. doi: 10.1016/j.amjmed.2016.03.024.
5. Overvad TF, Nielsen PB, Lip GYH. Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score [published online ahead of print August 12, 2016]. Eur Hear J Cardiovasc Pharmacother. http://dx.doi.org/10.1093/ehjcvp/pvw022. http://ehjcvp.oxfordjournals.org/content/early/2016/09/11/ehjcvp. pvw022.long. Accessed November 18, 2016.
6. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635-642. doi: 10.1016/j.jacc.2014.11.046.
7. Chao TF, Lip GY, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Chen TJ, Chiang CE, Chen SA. Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study. Stroke. 2016;47:2462-2469. doi: 10.1161/STROKEAHA.116.013880.
8. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
9. Nielsen PB, Larsen TB, Skjøth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study. Sci Rep. 2016;6:27410. doi: 10.1038/srep27410.
10. Friberg L, Skeppholm M, Terént A. Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol. 2015;65:225-232. doi: 10.1016/j. jacc.2014.10.052.
11. Aspberg S, Chang Y, Atterman A, Bottai M, Go AS, Singer DE. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J. 2016;37:3203-3210. doi: 10.1093/eurheartj/ehw077.
12. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297-305.
13. Connolly SJ, Eikelboom JW, Ng J, Hirsh J, Yusuf S, Pogue J, de Caterina R, Hohnloser S, Hart RG; ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med. 2011;155:579-586. doi: 10.7326/0003-4819-155-9-201111010-00004.
14. Lip GY, Skjøth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score: a comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost. 2015;114:826-834. doi: 10.1160/TH15-07-0565.
15. Fauchier L, Lecoq C, Clementy N, Bernard A, Angoulvant D, Ivanes F, Babuty D, Lip GY. Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: the Loire Valley Atrial Fibrillation Project. Chest. 2016;149:960-968. doi: 10.1378/chest.15-1622.